Drug Trial Radar · NCT05051930
A Clinical Trial of TQC3721 Suspension for Inhalation
Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
114
Planned (sponsor's estimate)
Start
Oct 18, 2021
Primary completion
Oct 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD)and asthma.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
TQC3721 suspension for inhalationDrug
Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
TQC3721 suspension placebo for inhalationDrug
Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse eventsTime frame: From the enrollment of the subjects to 72 hours after the last administration
- Incidence of adverse eventsTime frame: From the enrollment of the subjects to 72 hours after the last administration
- Number of adverse events related to the study drugTime frame: From the enrollment of the subjects to 72 hours after the last administration
- Incidence of adverse events associated with the study drugTime frame: From the enrollment of the subjects to 72 hours after the last administration
- Area Under The Curve(AUC)Time frame: Within 60 minutes before each administration, to 72 hours after administration
- Plasma drug peak concentration(Cmax )Time frame: Within 60 minutes before each administration, to 72 hours after administration
- Time to peak(Tmax)Time frame: Within 60 minutes before each administration, to 72 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.